Marinus Pharmaceuticals, Inc. announced the appointment of Christine Silverstein to its Board of Directors and Audit Committee. Ms. Silverstein is a seasoned finance executive with experience across both private and public biopharmaceutical companies and an aptitude for implementing strong financial strategy, corporate partnering, financial reporting, cash management and improving efficiencies within organizations. Ms. Silverstein currently serves as Chief Financial Officer (CFO) of Excision Biotherapeutics, Inc., and most recently served as CFO of Emendo Biotherapeutics (acquired in December 2020 by AnGes, Inc.).

She previously operated in various senior executive roles within the biotechnology industry, including Abeona Therapeutics, as CFO and Principal Financial Officer, and SCO Capital Partners, as managing director. Ms. Silverstein began her career in the financial services industry before moving to capital markets advisory firms, where she was instrumental in advising clients on transaction considerations and formulating effective U.S. public listing and financing strategies. A member of CHIEF and Women in Bio, two esteemed networks of exceptional female leaders, Ms. Silverstein holds a Bachelor of Science from the Peter Tobin College of Business at St.

John's University and has earned accreditations from the Financial Industry Regulatory Authority (FINRA) and Harvard University. She currently serves on the board of Abeona Therapeutics Inc., a biopharmaceutical company focused on rare pediatric diseases.